Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors

Pirouz Daftarian, Guang Yun Song, Saima Ali, Moshe Faynsod, Jeff Longmate, Don J. Diamond, Joshua D I Ellenhorn

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The p53 gene product is overexpressed by almost 50% of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated rejection of established p53-overexpressing tumors without stimulating autoimmunity by immunization with modified vaccinia Ankara-expressing murine p53 (MVAp53). Tumor rejection was enhanced through antibody-mediated CTL-associated antigen 4 (CTLA-4) blockade. We examined the role of synthetic oligodeoxynucleotides (ODN) containing unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODN) in enhancing MVAp53-mediated tumor rejection. CpG ODN with MVAp53 resulted in tumor rejection in BALB/c mice bearing poorly immunogenic 11A-1 murine mammary carcinomas or Meth A sarcomas and C57Bl/6 mice bearing MC-38 colon carcinomas. The effect was similar to that seen in tumor-bearing mice treated with MVAp53 along with CTLA-4 blockade. Monoclonal antibody depletion experiments demonstrated that the adjuvant effects of CpG ODN and CTLA-4 blockades were CD8 dependent. CpG ODN were partially natural killer cell dependent and ineffective in Toll-like Receptor 9-/- and interleukin 6-/- mice, whereas CTLA-4 blockade was partially CD4 dependent and functional in Toll-like Receptor 9-/- and interleukin 6-/- mice. In addition, when administered with MVAp53, both adjuvants enhanced p53-specific cytotoxicity and demonstrated an additive effect when combined. The combination of CpG ODN and CTLA-4 blockade worked synergistically to reject palpable 11A-1 and MC-38 tumors. These experiments demonstrate the potential for augmenting MVAp53-mediated antitumor immunity using CpG ODN and CTLA-4 blockade. This cell-free immunotherapy approach is a candidate for evaluation in cancer patients.

Original languageEnglish (US)
Pages (from-to)5407-5414
Number of pages8
JournalCancer Research
Volume64
Issue number15
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Oligodeoxyribonucleotides
Cytosine
Vaccinia
Guanine
Immunization
Phosphates
Antigens
Neoplasms
Toll-Like Receptor 6
Toll-Like Receptor 9
Immunotherapy
Interleukin-6
p53 Genes
Autoimmunity
Natural Killer Cells
Sarcoma
Immunity
Colon
Monoclonal Antibodies
Breast Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Daftarian, P., Song, G. Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., & Ellenhorn, J. D. I. (2004). Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Research, 64(15), 5407-5414. https://doi.org/10.1158/0008-5472.CAN-04-0169

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. / Daftarian, Pirouz; Song, Guang Yun; Ali, Saima; Faynsod, Moshe; Longmate, Jeff; Diamond, Don J.; Ellenhorn, Joshua D I.

In: Cancer Research, Vol. 64, No. 15, 01.08.2004, p. 5407-5414.

Research output: Contribution to journalArticle

Daftarian, P, Song, GY, Ali, S, Faynsod, M, Longmate, J, Diamond, DJ & Ellenhorn, JDI 2004, 'Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors', Cancer Research, vol. 64, no. 15, pp. 5407-5414. https://doi.org/10.1158/0008-5472.CAN-04-0169
Daftarian, Pirouz ; Song, Guang Yun ; Ali, Saima ; Faynsod, Moshe ; Longmate, Jeff ; Diamond, Don J. ; Ellenhorn, Joshua D I. / Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. In: Cancer Research. 2004 ; Vol. 64, No. 15. pp. 5407-5414.
@article{166d08c7a380417c88345e283751c948,
title = "Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors",
abstract = "The p53 gene product is overexpressed by almost 50{\%} of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated rejection of established p53-overexpressing tumors without stimulating autoimmunity by immunization with modified vaccinia Ankara-expressing murine p53 (MVAp53). Tumor rejection was enhanced through antibody-mediated CTL-associated antigen 4 (CTLA-4) blockade. We examined the role of synthetic oligodeoxynucleotides (ODN) containing unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODN) in enhancing MVAp53-mediated tumor rejection. CpG ODN with MVAp53 resulted in tumor rejection in BALB/c mice bearing poorly immunogenic 11A-1 murine mammary carcinomas or Meth A sarcomas and C57Bl/6 mice bearing MC-38 colon carcinomas. The effect was similar to that seen in tumor-bearing mice treated with MVAp53 along with CTLA-4 blockade. Monoclonal antibody depletion experiments demonstrated that the adjuvant effects of CpG ODN and CTLA-4 blockades were CD8 dependent. CpG ODN were partially natural killer cell dependent and ineffective in Toll-like Receptor 9-/- and interleukin 6-/- mice, whereas CTLA-4 blockade was partially CD4 dependent and functional in Toll-like Receptor 9-/- and interleukin 6-/- mice. In addition, when administered with MVAp53, both adjuvants enhanced p53-specific cytotoxicity and demonstrated an additive effect when combined. The combination of CpG ODN and CTLA-4 blockade worked synergistically to reject palpable 11A-1 and MC-38 tumors. These experiments demonstrate the potential for augmenting MVAp53-mediated antitumor immunity using CpG ODN and CTLA-4 blockade. This cell-free immunotherapy approach is a candidate for evaluation in cancer patients.",
author = "Pirouz Daftarian and Song, {Guang Yun} and Saima Ali and Moshe Faynsod and Jeff Longmate and Diamond, {Don J.} and Ellenhorn, {Joshua D I}",
year = "2004",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-04-0169",
language = "English (US)",
volume = "64",
pages = "5407--5414",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors

AU - Daftarian, Pirouz

AU - Song, Guang Yun

AU - Ali, Saima

AU - Faynsod, Moshe

AU - Longmate, Jeff

AU - Diamond, Don J.

AU - Ellenhorn, Joshua D I

PY - 2004/8/1

Y1 - 2004/8/1

N2 - The p53 gene product is overexpressed by almost 50% of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated rejection of established p53-overexpressing tumors without stimulating autoimmunity by immunization with modified vaccinia Ankara-expressing murine p53 (MVAp53). Tumor rejection was enhanced through antibody-mediated CTL-associated antigen 4 (CTLA-4) blockade. We examined the role of synthetic oligodeoxynucleotides (ODN) containing unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODN) in enhancing MVAp53-mediated tumor rejection. CpG ODN with MVAp53 resulted in tumor rejection in BALB/c mice bearing poorly immunogenic 11A-1 murine mammary carcinomas or Meth A sarcomas and C57Bl/6 mice bearing MC-38 colon carcinomas. The effect was similar to that seen in tumor-bearing mice treated with MVAp53 along with CTLA-4 blockade. Monoclonal antibody depletion experiments demonstrated that the adjuvant effects of CpG ODN and CTLA-4 blockades were CD8 dependent. CpG ODN were partially natural killer cell dependent and ineffective in Toll-like Receptor 9-/- and interleukin 6-/- mice, whereas CTLA-4 blockade was partially CD4 dependent and functional in Toll-like Receptor 9-/- and interleukin 6-/- mice. In addition, when administered with MVAp53, both adjuvants enhanced p53-specific cytotoxicity and demonstrated an additive effect when combined. The combination of CpG ODN and CTLA-4 blockade worked synergistically to reject palpable 11A-1 and MC-38 tumors. These experiments demonstrate the potential for augmenting MVAp53-mediated antitumor immunity using CpG ODN and CTLA-4 blockade. This cell-free immunotherapy approach is a candidate for evaluation in cancer patients.

AB - The p53 gene product is overexpressed by almost 50% of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated rejection of established p53-overexpressing tumors without stimulating autoimmunity by immunization with modified vaccinia Ankara-expressing murine p53 (MVAp53). Tumor rejection was enhanced through antibody-mediated CTL-associated antigen 4 (CTLA-4) blockade. We examined the role of synthetic oligodeoxynucleotides (ODN) containing unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODN) in enhancing MVAp53-mediated tumor rejection. CpG ODN with MVAp53 resulted in tumor rejection in BALB/c mice bearing poorly immunogenic 11A-1 murine mammary carcinomas or Meth A sarcomas and C57Bl/6 mice bearing MC-38 colon carcinomas. The effect was similar to that seen in tumor-bearing mice treated with MVAp53 along with CTLA-4 blockade. Monoclonal antibody depletion experiments demonstrated that the adjuvant effects of CpG ODN and CTLA-4 blockades were CD8 dependent. CpG ODN were partially natural killer cell dependent and ineffective in Toll-like Receptor 9-/- and interleukin 6-/- mice, whereas CTLA-4 blockade was partially CD4 dependent and functional in Toll-like Receptor 9-/- and interleukin 6-/- mice. In addition, when administered with MVAp53, both adjuvants enhanced p53-specific cytotoxicity and demonstrated an additive effect when combined. The combination of CpG ODN and CTLA-4 blockade worked synergistically to reject palpable 11A-1 and MC-38 tumors. These experiments demonstrate the potential for augmenting MVAp53-mediated antitumor immunity using CpG ODN and CTLA-4 blockade. This cell-free immunotherapy approach is a candidate for evaluation in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=3442883353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442883353&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-0169

DO - 10.1158/0008-5472.CAN-04-0169

M3 - Article

C2 - 15289349

AN - SCOPUS:3442883353

VL - 64

SP - 5407

EP - 5414

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -